Influence of particle diameter on aerosolization performance and release of budesonide loaded mesoporous silica particles

van der Zwaan, Irès; Pilkington, Georgia A.; Frenning, Göran; Ekström, Mikael; Valetti, Sabrina; Pitcairn, Gary R.; Feiler, Adam

doi:10.1016/j.ejps.2024.106828

Cited by 1 publication

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each inhaler was filled with 10 mg of freeze-dried formulation (LYS-MSP). Using the Next Generation Impactor (NGI), the loaded dose was aerosolised at 64 L/min at pressure drop of 4 kPa until a total of 4 L of air was drawn through, conditions similar to those reported in literature (Buttini et al., 2016 ; van der Zwaan et al., 2024 ). A coating solution of 13% v/v Brij® 35 and 87% v/v glycerol in ethanol was used in each of the NGI stage cups to minimize particle bounce during the aerosolization.…”

Section: Methodsmentioning

confidence: 98%

Disordered mesoporous silica particles: an emerging platform to deliver proteins to the lungs

Rocío Hernández,

Bogdanova,

Campos Pacheco

et al. 2024

Drug Delivery

Self Cite

View full text Add to dashboard Cite

Pulmonary delivery and formulation of biologics are among the more complex and growing scientific topics in drug delivery. We herein developed a dry powder formulation using disordered mesoporous silica particles (MSP) as the sole excipient and lysozyme, the most abundant antimicrobial proteins in the airways, as model protein. The MSP had the optimal size for lung deposition (2.43 ± 0.13 µm). A maximum lysozyme loading capacity (0.35 mg/mg) was achieved in 150 mM PBS, which was seven times greater than that in water. After washing and freeze-drying, we obtained a dry powder consisting of spherical, non-aggregated particles, free from residual buffer, or unabsorbed lysozyme. The presence of lysozyme was confirmed by TGA and FT-IR, while N 2 adsorption/desorption and SAXS analysis indicate that the protein is confined within the internal mesoporous structure. The dry powder exhibited excellent aerodynamic performance (fine particle fraction <5 µm of 70.32%). Lysozyme was released in simulated lung fluid in a sustained kinetics and maintaining high enzymatic activity (71–91%), whereas LYS-MSP were shown to degrade into aggregated nanoparticulate microstructures, reaching almost complete dissolution (93%) within 24 h. MSPs were nontoxic to in vitro lung epithelium. The study demonstrates disordered MSP as viable carriers to successfully deliver protein to the lungs, with high deposition and retained activity.

show abstract

Section: Methodsmentioning

confidence: 98%